Healthcare Industry News: Adaptive Radiation Therapy
News Release - July 23, 2013
RaySearch Laboratories: RayStation(R) 4.0 ReleasedSTOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (STO:RAYB) announces that version 4.0 of RaySearch's RayStation® treatment planning system has been released for clinical use in several European countries, USA, Japan, Australia and New Zealand, and is scheduled for market release in Canada, China, and South Korea.
The new version includes a wide range of new features and improvements. For example, RayStation® contains a unique solution enabling a more efficient treatment planning process called Multi-criteria optimization. This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process. With RayStation® 4.0 the tool for Multi-criteria optimization is extended with support for creating VMAT treatments in addition to IMRT. This means that the system stands out as the most intuitive treatment planning system for creating all advanced radiation treatments.
Another new feature in RayStation® 4.0 is Atlas-based segmentation in the patient modeling module which is a complement to the existing Model-based segmentation tool. Atlas-based segmentation utilizes a structure template framework to create a versatile auto-segmentation tool. It allows the users to create organ atlases from clinical cases and new patients can then be segmented by automatic deformable registration of the best-matching atlas in the clinical database. The geometries in each atlas can be manually contoured or generated with model-based segmentation.
RayStation® 4.0 also contains numerous improvements and additions throughout the system such as several added features in 3D-CRT planning including support for static arcs. It offers even faster optimizations due to refined multithreading and improved handling of GUI updates during optimization. In the electron beam design module support has been added for all relevant collimators and the proton beam design module now supports the Mevion S250 machine. For a full list of new features please refer to the release notes.
RayStation® 4.0 will be demonstrated at the upcoming annual AAPM meeting which will be held August 4-8 in Indianapolis, Indiana.
“I firmly believe RayStation® is by far the most efficient tool on the market to create advanced radiation treatments of the highest quality and with version 4.0 we take another big leap forward in terms of speed and usability”, says Johan Löf, CEO of RaySearch.
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D Adaptive Radiation Therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.